Systematic screening using FRAX


Journal

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 16 04 2019
accepted: 20 08 2019
pubmed: 14 10 2019
medline: 5 2 2021
entrez: 14 10 2019
Statut: ppublish

Résumé

In the large community-based SCOOP trial, systematic fracture risk screening using FRAX In the SCreening of Older wOmen for Prevention of fracture (SCOOP) trial, we investigated the effect of the screening intervention on subsequent long-term self-reported adherence to anti-osteoporosis medications (AOM). SCOOP was a primary care-based UK multicentre trial of screening for fracture risk. A total of 12,483 women (70-85 years) were randomised to either usual NHS care, or assessment using the FRAX The mean (SD) age of participants was 75.6 (4.2) years, with 6233 randomised to screening and 6250 to the control group. Of those participants identified at high fracture risk in the screening group, 38.2% of those on treatment at 6 months were still treated at 60 months, whereas the corresponding figure for the control group was 21.6%. Older age was associated with poorer adherence (OR per year increase in age 0.96 [95% CI 0.93, 0.99], p = 0.01), whereas history of parental hip fracture was associated with greater rate adherence (OR 1.67 [95% CI 1.23, 2.26], p < 0.01). Systematic fracture risk screening using FRAX

Identifiants

pubmed: 31606826
doi: 10.1007/s00198-019-05142-z
pii: 10.1007/s00198-019-05142-z
pmc: PMC6952271
mid: EMS84838
doi:

Substances chimiques

Diphosphonates 0

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-75

Subventions

Organisme : Medical Research Council
ID : MC_U147585827
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U147585819
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_A620_1014
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12011/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P020941/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400491
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U147585824
Pays : United Kingdom

Investigateurs

N Crabtree (N)
H Duffy (H)
J Parle (J)
F Rashid (F)
K Stant (K)
K Taylor (K)
C Thomas (C)
E Knox (E)
C Tenneson (C)
H Williams (H)
D Adams (D)
V Bion (V)
J Blacklock (J)
T Dyer (T)
S Bratherton (S)
M Fidler (M)
K Knight (K)
C McGurk (C)
K Smith (K)
S Young (S)
K Collins (K)
J Cushnaghan (J)
C Arundel (C)
K Bell (K)
L Clark (L)
S Collins (S)
S Gardner (S)
N Mitchell (N)

Références

J Bone Miner Res. 2018 May;33(5):845-851
pubmed: 29470854
J Bone Miner Res. 2016 Nov;31(11):2008-2015
pubmed: 27377877
Arch Osteoporos. 2017 Dec;12(1):43
pubmed: 28425085
J Bone Miner Res. 2015 Dec;30(12):2179-87
pubmed: 26018247
Osteoporos Int. 2007 Aug;18(8):1023-31
pubmed: 17308956
Osteoporos Int. 2012 Oct;23(10):2507-15
pubmed: 22314936
J Bone Miner Res. 2014 Sep;29(9):1926-8
pubmed: 24956507
Fam Pract. 2012 Apr;29(2):235-42
pubmed: 21908537
Osteoporos Int. 2017 Mar;28(3):767-774
pubmed: 28093634
J Womens Health (Larchmt). 2013 Nov;22(11):915-29
pubmed: 24131320
Osteoporos Int. 2017 Dec;28(12):3495-3500
pubmed: 28861636
Arch Osteoporos. 2013;8:136
pubmed: 24113837
World Health Organ Tech Rep Ser. 1994;843:1-129
pubmed: 7941614
Soc Sci Med. 2011 Sep;73(6):808-15
pubmed: 21813219
Mayo Clin Proc. 2007 Dec;82(12):1493-501
pubmed: 18053457
Osteoporos Int. 2017 May;28(5):1507-1529
pubmed: 28175979
Lancet. 2018 Feb 24;391(10122):741-747
pubmed: 29254858
Calcif Tissue Int. 2010 Mar;86(3):202-210
pubmed: 20063188
J Bone Miner Res. 2018 Jun;33(6):1020-1026
pubmed: 29480960
PLoS One. 2014 Jan 02;9(1):e83552
pubmed: 24392086
Osteoporos Int. 2011 Oct;22(10):2565-73
pubmed: 21617992
Osteoporos Int. 2013 Dec;24(12):2907-18
pubmed: 23636230
Osteoporos Int. 2011 Jan;22(1):27-35
pubmed: 20358360
Br J Clin Pharmacol. 2016 Jul;82(1):268-79
pubmed: 27005306
Pharmacoepidemiol Drug Saf. 2014 Dec;23(12):1303-11
pubmed: 25174626
Arch Osteoporos. 2016 Dec;11(1):25
pubmed: 27465509
Osteoporos Int. 2016 Nov;27(11):3197-3206
pubmed: 27283403

Auteurs

C M Parsons (CM)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, SO16 6YD, UK.

N Harvey (N)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, SO16 6YD, UK.
NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.

L Shepstone (L)

University of East Anglia, Norwich, UK.

J A Kanis (JA)

Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK.
Institute for Health and Ageing, Catholic University of Australia, Melbourne, Australia.

E Lenaghan (E)

University of East Anglia, Norwich, UK.

S Clarke (S)

Bristol Medical School, University of Bristol, Bristol, UK.

R Fordham (R)

University of East Anglia, Norwich, UK.

N Gittoes (N)

Centre for Endocrinology, Diabetes and Metabolism, Queen Elizabeth Hospital, Birmingham, UK.

I Harvey (I)

University of East Anglia, Norwich, UK.

R Holland (R)

University of East Anglia, Norwich, UK.

N M Redmond (NM)

Bristol Medical School, University of Bristol, Bristol, UK.
NIHR CLAHRC West, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.

A Howe (A)

University of East Anglia, Norwich, UK.

T Marshall (T)

University of East Anglia, Norwich, UK.

T J Peters (TJ)

Bristol Medical School, University of Bristol, Bristol, UK.

D Torgerson (D)

University of York, York, UK.

T W O'Neill (TW)

Arthritis Research UK Centre for Epidemiology, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
NIHR Manchester Biomedical Research Centre, Manchester University Hospitals Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

E McCloskey (E)

Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK.
Mellanby Centre for Bone Research, Centre for Integrated Research in Musculoskeletal Ageing, University of Sheffield, Sheffield, UK.
Sheffield Teaching Hospitals Foundation Trust, Sheffield, UK.

C Cooper (C)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, SO16 6YD, UK. cc@mrc.soton.ac.uk.
NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK. cc@mrc.soton.ac.uk.
NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. cc@mrc.soton.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH